FibroGen Management
Management criteria checks 2/4
FibroGen's CEO is Thane Wettig, appointed in Jul 2023, has a tenure of 1.33 years. total yearly compensation is $3.64M, comprised of 15.7% salary and 84.3% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $86.25K. The average tenure of the management team and the board of directors is 4 years and 5.9 years respectively.
Key information
Thane Wettig
Chief executive officer
US$3.6m
Total compensation
| CEO salary percentage | 15.7% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 4yrs |
| Board average tenure | 5.9yrs |
Recent management updates
Recent updates
Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding
Oct 29
The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%
Aug 19Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding
Jul 04FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward
Jun 06Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains
May 28Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet
May 07FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Mar 22There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise
Feb 05FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%
Dec 22A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)
Nov 24Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)
Apr 18Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
Feb 13The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts
Nov 12Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
Oct 09FibroGen completes patient enrollment for Roxadustat to treat anemia in patients
Aug 26FibroGen Q2 2022 Earnings Preview
Aug 05Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?
Jul 06Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?
Mar 31Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook
Mar 05Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?
Dec 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$122m |
| Jun 30 2024 | n/a | n/a | -US$168m |
| Mar 31 2024 | n/a | n/a | -US$240m |
| Dec 31 2023 | US$4m | US$573k | -US$284m |
| Sep 30 2023 | n/a | n/a | -US$294m |
| Jun 30 2023 | n/a | n/a | -US$322m |
| Mar 31 2023 | n/a | n/a | -US$307m |
| Dec 31 2022 | US$3m | US$535k | -US$294m |
| Sep 30 2022 | n/a | n/a | -US$362m |
| Jun 30 2022 | n/a | n/a | -US$220m |
| Mar 31 2022 | n/a | n/a | -US$281m |
| Dec 31 2021 | US$3m | US$510k | -US$290m |
| Sep 30 2021 | n/a | n/a | -US$215m |
| Jun 30 2021 | n/a | n/a | -US$231m |
| Mar 31 2021 | n/a | n/a | -US$183m |
| Dec 31 2020 | US$4m | US$263k | -US$189m |
Compensation vs Market: Thane's total compensation ($USD3.64M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Thane's compensation has increased whilst the company is unprofitable.
CEO
Thane Wettig (59 yo)
1.3yrs
Tenure
US$3,640,829
Compensation
Mr. Thane Wettig serves as Director of FibroGen, Inc. since October 2, 2023. He serves as Chief Executive Officer at FibroGen, Inc. since October 2, 2023 and served as Interim Chief Executive Officer since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | US$3.64m | 0.22% $ 86.2k | |
| Senior VP & CFO | 3.2yrs | US$3.09m | 0.082% $ 32.0k | |
| Senior Vice President of China Operations | 17.8yrs | US$3.11m | 0.30% $ 117.8k | |
| Founder | 29.8yrs | no data | no data | |
| Vice President of Corporate FP&A and Investor Relations | no data | no data | no data | |
| Chief Legal Officer | 8.6yrs | no data | no data | |
| Chief People Officer | 3.5yrs | no data | no data | |
| Chief Business Officer | 4yrs | no data | no data | |
| Senior VP of Regulatory | less than a year | no data | no data | |
| Secretary | 31.8yrs | US$27.13k | no data |
4.0yrs
Average Tenure
56yo
Average Age
Experienced Management: FGEN's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | US$3.64m | 0.22% $ 86.2k | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 9.1yrs | US$385.53k | 0.025% $ 9.9k | |
| Independent Chairman of the Board | 14.6yrs | US$499.58k | 0.081% $ 31.6k | |
| Independent Director | 5.9yrs | US$375.53k | 0.023% $ 9.0k | |
| Independent Director | 4.3yrs | US$373.03k | 0.020% $ 7.6k |
5.9yrs
Average Tenure
63yo
Average Age
Experienced Board: FGEN's board of directors are considered experienced (5.9 years average tenure).